A new medicine can spend years moving from laboratory research to human trials before reaching the market. During that journey, pharmaceutical companies need scientists to develop molecules, chemists to refine manufacturing processes and specialised facilities to produce medicines under strict quality standards.
Hyderabad-based Sai Life Sciences has built its business around providing these services.
Unlike pharmaceutical companies that primarily sell their own branded or generic medicines, Sai Life Sciences works behind the scenes for global drug developers. Its customers include large pharmaceutical companies and biotechnology businesses developing new treatments.
The company is now expanding its research and manufacturing capabilities as drug developers increasingly outsource specialised work. Its opportunity lies in becoming a long-term development partner rather than merely a supplier hired for individual laboratory assignments.
Also Read: Tonbo Imaging: The Indian Defence Technology Company Building Eyes for Modern Warfare
How Sai Life Sciences Makes Money
Sai Life Sciences operates as a contract research, development and manufacturing organisation, commonly called a CRDMO.
Its business has two principal components. The contract research organisation, or CRO, division supports early-stage drug discovery. The contract development and manufacturing organisation, or CDMO, division helps customers develop manufacturing processes and produce pharmaceutical ingredients for clinical trials and commercial use.
Customers pay for scientific services, research programmes, development work and manufacturing contracts.
A biotechnology company might initially engage Sai Life Sciences to develop promising drug molecules. If the programme progresses, the same customer could require process development, clinical manufacturing and eventually commercial production.
Also Read: Lupin: How India’s Pharma Giant Is Moving Beyond Generic Medicines
This creates an opportunity to maintain relationships across several stages of a medicine’s development.
However, not every research project becomes a commercial product. Drug development involves scientific uncertainty, and customer programmes can be delayed, discontinued or transferred to another manufacturer.
Drug Discovery Is the Starting Point
Sai Life Sciences’ research business helps pharmaceutical companies identify and develop potential new medicines.
Its scientists work across medicinal chemistry, synthetic chemistry, biology, drug metabolism, pharmacokinetics and related research disciplines.
Also Read: Blue Star: The Indian AC Maker Building a Bigger Business Beyond Home Cooling
The work is highly specialised. Researchers must understand how a molecule behaves, whether it interacts with the intended biological target and how its chemical structure might be improved.
A customer may begin with several potential compounds before narrowing the programme to a smaller group of candidates.
Sai Life Sciences earns revenue by providing the scientific expertise, laboratory infrastructure and research capacity required for this process.
The company has been developing integrated discovery services, allowing customers to combine different scientific capabilities within a coordinated programme.
Also Read: Jio Platforms: From India’s Biggest Telecom Network to a Digital Technology Powerhouse
For smaller biotechnology businesses, outsourcing can reduce the need to build extensive laboratories and recruit every specialist internally.
For large pharmaceutical companies, it provides additional research capacity and access to particular technical skills.
Manufacturing Creates a Longer Business Relationship
Drug discovery is only one part of Sai Life Sciences’ operations.
Once a promising medicine advances toward clinical development, its manufacturing process must become more reliable and scalable.
Also Read: Piramal Pharma: The Global Drug Manufacturing Business Building Its Next Growth Engine
Producing a small quantity in a research laboratory is very different from manufacturing pharmaceutical ingredients consistently for clinical trials or commercial distribution.
Sai Life Sciences helps customers develop these processes and manufacture active pharmaceutical ingredients, or APIs.
Its CDMO business covers process research, development, clinical supply and commercial manufacturing.
The commercial attraction is that a successful medicine may require production over several years. This can create a more sustained relationship than an early-stage research assignment.
But commercial manufacturing brings additional responsibilities. Facilities must meet regulatory standards, maintain consistent product quality and deliver materials according to agreed schedules.
Any interruption can affect the customer’s medicine supply and the manufacturer’s reputation.
Global Customers and the Hyderabad Advantage
Sai Life Sciences works with more than 300 pharmaceutical and biotechnology companies internationally.
Its global operating model combines research and customer-facing capabilities in the United States and United Kingdom with substantial scientific and manufacturing operations in India.
Also Read: PC Jeweller: From Debt Crisis to a Debt-Free Jewellery Retailer — Can Its Next Expansion Deliver?
Hyderabad provides access to an established pharmaceutical industry, experienced scientists, chemical manufacturing expertise and supporting suppliers.
This allows Sai Life Sciences to serve international customers while using India’s research and manufacturing ecosystem.
The company benefits when customers prefer to outsource specialised work rather than undertake every development activity within their own facilities.
However, customer relationships are not guaranteed to continue indefinitely. Pharmaceutical companies regularly review research priorities, development budgets and manufacturing partnerships.
Also Read: Vodafone Idea: Can India’s Telecom Challenger Turn Its 5G Expansion Into a Business Comeback?
For Sai Life Sciences, maintaining technical quality and dependable execution is essential to winning repeat business.
Moving Into More Complex Medicines
The company is expanding beyond conventional small-molecule development into newer pharmaceutical technologies.
These include peptides, oligonucleotides and antibody-drug conjugates, commonly known as ADCs.
ADCs are particularly interesting because they combine a targeted antibody with a potent drug component. Their development requires specialised chemistry, careful handling and sophisticated manufacturing processes.
Sai Life Sciences is investing in capabilities that support these emerging treatment categories.
Such technologies can create opportunities for higher-value scientific work because fewer suppliers possess the necessary expertise and infrastructure.
The investment requirements are also greater.
Advanced facilities, specialised equipment and highly trained employees are expensive. Customers may take considerable time to progress their programmes, meaning new capacity does not always generate immediate revenue.
The company’s challenge is to invest ahead of demand without building facilities that remain underutilised.
Financial Performance Shows a Growing Business
Sai Life Sciences’ latest September 2026 quarter showed growth across its research and manufacturing operations.
Revenue increased as both CRO and CDMO activities expanded, while operating profit also improved.
The company has been spending heavily on additional capacity, reflecting management’s expectation of greater demand from pharmaceutical customers.
Also Read: Delhivery Business Analysis: How India’s Technology-Driven Logistics Company Makes Money
Financial Performance
| Measure | Q2 FY2026-27 | Q2 FY2025-26 |
|---|---|---|
| Revenue from operations | ₹659 crore | ₹537 crore |
| EBITDA | ₹187 crore | ₹156 crore |
| EBITDA margin | 28% | 29% |
| Profit after tax | ₹98 crore | ₹84 crore |
| Additional measure | H1 FY2026-27 |
|---|---|
| Revenue from operations | ₹1,213 crore |
| EBITDA | ₹335 crore |
| Profit after tax | ₹172 crore |
| Capital expenditure | ₹621 crore |
| CDMO share of revenue | 62% |
| CRO share of revenue | 38% |
The figures show an expanding business, although the quarterly EBITDA margin moderated despite higher revenue.
The capital expenditure is particularly important. New research and manufacturing facilities require spending before they can contribute fully to earnings.
Management expects a stronger second half of the financial year as customer programmes progress and additional capacity begins operating.
Also Read: VRL Logistics: Inside India’s Road Transport Giant and Its Expanding Logistics Business
The financial outcome will depend on how quickly that investment translates into productive utilisation and profitable contracts.
Competition in the Global CRDMO Industry
Sai Life Sciences competes with Indian and international companies providing pharmaceutical research and manufacturing services.
Indian businesses such as Syngene International, Divi’s Laboratories and Piramal Pharma participate in overlapping areas of the pharmaceutical outsourcing market, although their service portfolios and commercial models differ.
International competitors include specialised research organisations and large contract manufacturers serving global pharmaceutical companies.
Also Read: ITC Farm-to-Food Business Model: Sourcing, Brands and Cash Flow
Competition is not based on price alone.
Customers consider scientific expertise, regulatory compliance, manufacturing reliability, intellectual property protection and the ability to handle complex projects.
A development programme may involve years of research and substantial financial investment. Pharmaceutical companies therefore place considerable importance on choosing partners capable of maintaining consistent standards.
Sai Life Sciences’ ability to provide services from discovery through commercial manufacturing is a competitive advantage when customers prefer integrated outsourcing relationships.
Also Read: ServiceNow: From IT Ticketing to the AI Agent Operating System for Enterprises
Still, larger competitors may possess greater manufacturing capacity, broader geographic networks or more established positions in particular technologies.
Customer Concentration and Other Risks
One important risk is customer concentration.
Large pharmaceutical customers can account for a significant portion of revenue. Losing a major programme or experiencing delays in customer development plans can affect performance.
Drug development itself is unpredictable. A molecule may fail during testing, preventing it from progressing to later-stage manufacturing.
Also Read: Eternal: From Zomato to a Multi-Business Consumer Platform Built Around Blinkit
The company also faces regulatory and operational risks. Pharmaceutical manufacturing facilities require strict quality controls, while inspections and compliance requirements can influence production schedules.
Rapid expansion introduces another challenge.
Building new facilities increases depreciation, staffing and operating expenses. If customer demand develops more slowly than expected, profitability and cash generation may come under pressure.
Currency movements, international supply-chain disruptions and competition for specialised scientific talent can also influence operating costs.
Also Read: Policybazaar: From Insurance Comparison Website to India’s Digital Insurance Distribution Powerhouse
These factors make execution and capital allocation particularly important during periods of heavy investment.
What Could Drive Sai Life Sciences’ Future Growth?
The global pharmaceutical industry is becoming more specialised.
Developing complex medicines requires capabilities that many pharmaceutical and biotechnology companies prefer to access through external partners.
Sai Life Sciences is positioned to participate in this trend through its combination of research, process development and manufacturing services.
Also Read: Raymond: From Suits to High-Precision Engineering — The Transformation Is Just Beginning
Its integrated business model creates opportunities to deepen existing customer relationships. A company that begins with discovery research may later require clinical manufacturing or commercial supply.
Newer technologies such as ADCs and peptides could provide additional growth opportunities as pharmaceutical development programmes become more complex.
The company has also been strengthening relationships with large pharmaceutical customers through integrated outsourcing arrangements.
These partnerships could improve the visibility of future work, although the commercial contribution will depend on individual programme progress and contract execution.
Also Read: DMCC Speciality Chemicals: The 100-Year Chemical Company Building a New Specialty Business
The Long-Term Outlook
Sai Life Sciences operates in a part of the pharmaceutical industry where scientific expertise and manufacturing reliability are closely connected.
Its Hyderabad research and manufacturing base, international customer relationships and expanding technical capabilities provide a foundation for growth.
The opportunity is not simply to win more laboratory assignments. It is to participate in a greater portion of each customer’s drug development journey, from early research to commercial manufacturing.
That approach can create deeper relationships and potentially more durable revenue.
Also Read: Avalon Technologies: The EMS Company Quietly Building India’s Next Manufacturing Engine
But the business remains exposed to research failures, changing customer priorities and the financial demands of capacity expansion.
The next stage of Sai Life Sciences’ development will depend on whether its investments produce stronger customer engagement, higher facility utilisation and consistent cash generation.
For a company working largely behind the scenes of global medicine development, those operating measures will matter more than the number of new technologies it announces.
Disclaimer: This article is intended for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell securities. Investors should conduct independent research and consider their financial circumstances and risk tolerance before making investment decisions. Onetrader is not a SEBI-registered investment adviser or research analyst.
Also Read: IREDA: The Green Financing Powerhouse Funding India’s Renewable Energy Boom
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.
Need a laugh after all that money talk?
Paisa LOL: India's funniest finance page, with memes, comics, jokes and long funny stories.
